Literature DB >> 10912794

Predominant intracellular localization of the type I transforming growth factor-beta receptor and increased nuclear accumulation after growth arrest.

J C Zwaagstra1, A Guimond, M D O'Connor-McCourt.   

Abstract

Transforming growth factor-beta (TGF-beta) signaling requires the functional interaction of two distinct receptors, type I (RI) and type II (RII), at the cell surface. Exposure of cells to TGF-beta results in receptor internalization and down-regulation (Zwaagstra et al., 1999, Exp. Cell Res. 252, 352362); however, little is known about the subsequent fate of RI or RII. In this study the cellular distribution of RI was examined in cells before and after treatment with ligand. RI was localized by immunocytochemistry and confocal microscopy using two polyclonal antisera directed against two different epitopes, one in the C-terminal region and one in the N-terminal region of the cytoplasmic domain. The majority of RI molecules in untreated MvlLu and A549 cells were found to be intracellular. Treatment of MvlLu and A549 cells with 100 pM TGF-beta1 for 24 h at 37 degrees C caused a redistribution of surface RI on MvlLu cells, as evidenced by surface RI aggregation. Unexpectedly, this TGF-beta1 treatment also caused redistribution and accumulation of intracellular RI in and around the nucleus for both MvlLu and A549 cells. Nuclear accumulation of RI was also promoted independently of ligand receptor activation by treatment of MvlLu cells with olomoucine, an agent that results in growth arrest. The capacity of RI to localize in the nucleus was confirmed by microscopic examination of 293 cells transiently expressing RI fused to green fluorescent protein (RI-GFP). Olomoucine treatment of these cells resulted in the movement of RI-GFP into the nucleus. Our results indicate that growth arrest alters intracellular transport/routing of RI and may indicate that RI functions not only at the cell surface but inside the cell as well.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912794     DOI: 10.1006/excr.2000.4905

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Characterization of nuclear neurokinin 3 receptor expression in rat brain.

Authors:  C D Sladek; W Stevens; S R Levinson; Z Song; D D Jensen; F W Flynn
Journal:  Neuroscience       Date:  2011-09-08       Impact factor: 3.590

Review 2.  Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications.

Authors:  Hui-Wen Lo
Journal:  Discov Med       Date:  2010-07       Impact factor: 2.970

Review 3.  Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.

Authors:  Woody Han; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

Review 4.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

5.  Phosphorylation of ΔNp63α via a novel TGFβ/ALK5 signaling mechanism mediates the anti-clonogenic effects of TGFβ.

Authors:  Pratima Cherukuri; Andrew J DeCastro; Amanda L Balboni; Sondra L Downey; Jennifer Y Liu; Justine A Hutchinson; James DiRenzo
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

6.  Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation.

Authors:  J F Reilly; P A Maher
Journal:  J Cell Biol       Date:  2001-03-19       Impact factor: 10.539

Review 7.  Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.

Authors:  H-W Lo; M-C Hung
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

8.  FGF-2, TGFbeta-1, PDGF-A and respective receptors expression in pleomorphic adenoma myoepithelial cells: an in vivo and in vitro study.

Authors:  Lucyene Miguita; Elizabeth Ferreira Martinez; Ney Soares de Araújo; Vera Cavalcanti de Araújo
Journal:  J Appl Oral Sci       Date:  2010 Jan-Feb       Impact factor: 2.698

Review 9.  Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2.

Authors:  U Bertsch; C Röder; H Kalthoff; A Trauzold
Journal:  Cell Death Dis       Date:  2014-08-28       Impact factor: 8.469

10.  Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.

Authors:  Carmela Dantas-Barbosa; Tom Lesluyes; François Le Loarer; Fréderic Chibon; Isabelle Treilleux; Jean-Michel Coindre; Pierre Meeus; Mehdi Brahmi; Olivia Bally; Isabelle Ray-Coquard; Marie-Pierre Sunyach; Axel Le Cesne; Olivier Mir; Sylvie Bonvalot; Maud Toulmonde; Antoine Italiano; Pierre Saintigny; Myriam Jean-Denis; Francoise Ducimetiere; Dominique Ranchere; Hiba El Sayadi; Laurent Alberti; Jean-Yves Blay
Journal:  Br J Cancer       Date:  2017-10-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.